Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home versus hospital treatment with LMWH for acute non-massive pulmonary embolism
NL-OMON22733Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of low molecular weight heparin calcium in pulmonary embolism (PE) and venous thromboembolism (VTE) (2 arms), sponsored by GSK. Primary endpoints: Recurrent thromboembolic events, Major bleeding and 1 more. Started Feb 2009; status: active, not recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON22733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22733.